Rofecoxib as an alternative in aspirin hypersensitivity.
Hinrichs
R
R
Department of Dermatology, University of Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany.
Ritzkowsky
A
A
Hunzelmann
N
N
Krieg
T
T
Scharffetter-Kochanek
K
K
D000328:Adult; D001241:Aspirin / Q000009:adverse effects*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004342:Drug Hypersensitivity / Q000209:etiology*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D007783:Lactones / Q000627:therapeutic use*; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D019233:Retreatment; D013450:Sulfones
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin